Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Zepzelca: metastatic Small Cell Lung Cancer after prior therapy

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after prior platinum-based chemotherapy.

Broader topic: Small Cell Lung Cancer

Source population
Not part of this definition
Disease extent
metastatic
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
    1. class
      after prior platinum-based chemotherapy
      status
      required
    derivation status
    source-attested
    derivation note
    Scoped from the FDA approved indication for Zepzelca (lurbinectedin) (accelerated-approval table). Only dimensions stated in that wording are part of this definition.
    source wording
    Treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after prior platinum-based chemotherapy.

    Study evidence for this setting

    7 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    NCT01631552 · Source cited / selected · Scope: unclear

    Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

    6 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT02062632 · Registry condition search · Scope: unclear

    Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy

    6 outcome links · 1 safety-group records · 3 quality-of-life measures

    →

    NCT03154190 · Registry condition search · Scope: unclear

    Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

    6 outcome links · 2 safety-group records · 0 quality-of-life measures

    →

    NCT04234113 · Registry condition search · Scope: unclear

    Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

    6 outcome links · 17 safety-group records · 0 quality-of-life measures

    →

    NCT04514484 · Registry condition search · Scope: unclear

    Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

    6 outcome links · 1 safety-group records · 0 quality-of-life measures

    →

    NCT04579757 · Registry condition search · Scope: unclear

    Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

    6 outcome links · 9 safety-group records · 0 quality-of-life measures

    →

    NCT05551117 · Registry condition search · Scope: unclear

    A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

    6 outcome links · 4 safety-group records · 0 quality-of-life measures

    →
    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice